By Nascent Biotech Posted November 4, 2019 In SNAP25 autism copy2019-11-042019-11-04http://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.pngNascent Biotechhttp://www.nascentbiotech.com/wp-content/uploads/2015/06/nascent-logo-horiz-300.png200px200px 0 SNAP25 autism copy Recent PostsNascent Announces the Completion of Its Phase 1 Clinical TrialsNascent Completes Dosing Requirement in Final Cohort of Phase I Clinical TrialNBIO Fits Profile for Strategy Targeting Early Stage BiotechNascent Enrolls Final Patient Cohort in Phase I Brain Cancer Trial
